Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu.Alteogen will receive an upfront payment of $20 million, with another $280 million on offer from Daiichi Sankyo if the new formulation of Enhertu (trastuzumab deruxtecan) makes it to market and meets sales targets.If that does happen, HER2 inhibitor Enhertu could become the first drug in the antibody-drug conjugate (ADC) class to be delivered subcutaneously – which is a tall order for such a large molecule – rather than by intravenous infusion. That could make it possible for patients to receive the drug outside of clinic settings, and potentially even at home using a self-injector.Alteogen will use its Hybrozyme platform, including recombinant human hyaluronidase enzyme ALT-B4, to develop the new version of Enhertu.

第一三共与韩国生物技术公司Alteogen签署了一项价值高达3亿美元的协议，开发其与阿斯利康合作的抗癌药物Enhertu的皮下版本。Alteogen将获得2000万美元的预付款，如果Enhertu（曲妥珠单抗-德鲁替康）的新配方上市并达到销售目标，Daiichi Sankyo将提供另外2.8亿美元。如果真的发生了这种情况，HER2抑制剂Enhertu可能成为抗体-药物偶联物（ADC）类中第一种皮下递送的药物-这对于如此大的分子来说是一个很高的要求-而不是通过静脉输注。这可能使患者有可能在诊所之外接受药物治疗，甚至可能在家中使用自动注射器。Alteogen将使用其Hybrozyme平台，包括重组人透明质酸酶ALT-B4，开发新版本的Enhertu。

The enzyme temporarily hydrolyses hyaluronan in the extracellular matrix of the subcutaneous layer of skin, making it possible to deliver larger volumes of drug material and improve dispersion and absorption.It is a well-established approach, pioneered by Halozyme with its Enhanze technology which is already used in several marketed products, including Roche's rival HER2-targeting drugs Herceptin Hylecta (trastuzumab/hyaluronidase) and Phesgo (pertuzumab/trastuzumab/hyaluronidase).Last year, Alteogen also signed an agreement with Sandoz to develop Hybrozyme-based versions of an undisclosed biosimilar drug, with an option on two additional programmes, and it also has an alliance with MSD for the development of a subcutaneous version of its blockbuster cancer immunotherapy Keytruda (pembrolizumab).Financial terms of the Sandoz agreement were not disclosed, but MSD (known as Merck & Co i.

该酶暂时水解皮肤皮下层细胞外基质中的透明质酸，从而可以输送更大体积的药物并改善分散和吸收。这是一种成熟的方法，由Halozyme及其Enhanze技术开创，该技术已用于多种市售产品，包括罗氏的竞争对手HER2靶向药物Herceptin Hylecta（曲妥珠单抗/透明质酸酶）和Phesgo（帕妥珠单抗/曲妥珠单抗/透明质酸酶）。去年，Alteogen还与Sandoz签署了一项协议，开发一种未公开的生物仿制药的基于Hybrozyme的版本，可以选择另外两个项目，并且它还与MSD结成联盟，开发其重磅炸弹癌症免疫疗法Keytruda（pembrolizumab）的皮下版本。桑多斯协议的财务条款没有披露，但MSD（被称为默克公司i。